| Prev Close | 2.76 |
| Open | 2.76 |
| Day Low/High | 2.59 / 2.77 |
| 52 Wk Low/High | 0.57 / 4.24 |
| Volume | 1.52M |
| Avg Volume | 1.89M |
| Exchange | NASDAQ |
| Shares Outstanding | 118.87M |
| Market Cap | 332.83M |
| EPS | -0.60 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2017 and provided a business update.
AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Cowen and Company 38 th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at...
AVEO Oncology (NASDAQ:AVEO) today announced that the United Kingdom's National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending FOTIVDA ® (tivozanib) for...
AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced the presentation of preliminary results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA ®) in...
AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: LEERINK Partners 7th Annual Global Healthcare...
AVEO Oncology (NASDAQ: AVEO) today announced the appointment of John H.
Investors in AVEO Pharmaceuticals Inc saw new options become available this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new March 16th contracts and identified the following put contract of particular interest.
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from a multicenter, Phase 1b/2 study of FOTIVDA ® (tivozanib), a potent, selective, long half-life inhibitor of all three vascular endothelial growth...
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 36th Annual J.
AVEO Oncology (NASDAQ:AVEO) today announced that it has completed the refinancing of its existing $20.
Investors in AVEO Pharmaceuticals Inc saw new options become available this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new February 16th contracts and identified the following call contract of particular interest.
Investors in AVEO Pharmaceuticals Inc saw new options begin trading this week, for the July 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Nikhil Mehta, Ph.
EUSA Pharma and AVEO Oncology (NASDAQ:AVEO) today announced the first commercial launch of FOTIVDA ® (tivozanib) with the initiation of product sales in Germany.
AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences: Jefferies 2017 London Healthcare Conference...
AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2017 and provided a business update.
AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib (FOTIVDA ®) in...
AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib (FOTIVDA ®) in...
AVEO Oncology (NASDAQ:AVEO) today announced that results from the Phase 1 portion of the Phase 1/2 TiNivo study will be presented in an oral presentation at the 16th International Kidney Cancer Symposium, to be held...
AVEO Oncology (NASDAQ:AVEO) today announced the completion of a pre-planned futility analysis of the Phase 3 TIVO-3 trial, the Company's randomized, controlled, multi-center, open-label study to compare FOTIVDA ®...
There's action in Global Blood Therapeutics and Antares Pharma.
AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA ® (tivozanib), has opted into the Phase 1/2 TiNivo study.
AVEO Oncology (NASDAQ:AVEO) today announced the receipt of a $4 million research and development payment from EUSA Pharma related to the approval of FOTIVDA ® (tivozanib) for the treatment of adult patients with...
As a Miami resident, I've learned the value of hurricane preparation and the 'Jensen Rules'.
As a Florida resident, I've learned the value of preparation and the 'Jensen Rules'.
AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences: The 19 th Annual Rodman & Renshaw...
AVEO Oncology (NASDAQ: AVEO) today announced that the European Commission (EC) has approved FOTIVDA ® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus...
AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2017, and provided a business update.
